Last updated: February 13, 2026
Product Overview
NDC 69087-0237 corresponds to a medication marketed under the brand Relyvrio (leucinostatin B, MS-222, or related formulation), used primarily for the treatment of ALS (amyotrophic lateral sclerosis). The drug gained accelerated approval from the FDA in late 2022, addressing a significant unmet need. Its unique mechanism involves targeting neurodegeneration pathways.
Market Landscape
The ALS market is relatively small but growing with increased research funding and innovative therapies.
- Market Size: The global ALS market was valued at approximately $170 million in 2022[1]. It is projected to reach around $300 million by 2030, with a compound annual growth rate (CAGR) of about 7.3%.
- Key Players: Existing drugs include Riluzole (marketed since 1995) and Edaravone (since 2017). The entry of Relyvrio introduces a new mechanism and option for clinicians.
- Patient Population: Estimated at 5,000 to 7,000 U.S. patients diagnosed annually; global estimates reach roughly 20,000 new cases yearly[2].
- Competitive Advantage: Relyvrio's clinical profile offers improved symptom management or slows progression, impacting its market penetration positively.
Pricing & Reimbursement Outlook
- Pricing Strategy: The initial wholesale acquisition cost (WAC) is expected to be set between $50,000 and $70,000 annually per patient, aligning with prices for ALS therapies such as Edaravone (~$40,000–$50,000) and Riluzole (~$5,000). The high end reflects the innovative status and market exclusivity.
- Price Comparisons:
- Edaravone: ~ $50,000/year
- Riluzole: ~$5,000/year
- The initial price for Relyvrio likely aligns closer to Edaravone due to similar clinical benefits and regulatory pathways.
- Reimbursement Trends: Payors, including Medicare/Medicaid and private insurers, are expected to approve standard coverage given the high unmet need and recent accelerated approval. Pricing negotiations will influence net prices, with discounts of 20-30% common for managed care contracts.
Regulatory and Commercial Risks
- Regulatory Landscape: Continued approval depends on confirmatory trials demonstrating safety and efficacy.
- Market Penetration: As a new entrant, Relyvrio may face delays in uptake due to clinician familiarity and existing prescribing habits centered around Riluzole and Edaravone.
- Pricing Pressure: Future biosimilars or emerging therapies, such as gene therapies (e.g., tofersen), could suppress prices.
Future Price Projections
| Year |
Estimated Price Range |
Notes |
| 2023 |
$50,000 – $70,000 |
Launch price, aligned with current ALS treatments |
| 2025 |
$45,000 – $65,000 |
Price stabilization, slight discounts for payors |
| 2030 |
$40,000 – $60,000 |
Competitive pressures, pipeline developments |
Market growth is driven by increasing awareness, expanding diagnostic capacity, and ongoing research. The projected gross revenue for Relyvrio by 2025 could range from $80 million to $130 million, assuming a conservative market penetration of 15-20% among eligible ALS patients.
Key Contributors and Challenges
- Reimbursement Policies: Favorable coverage will boost sales; restrictive policies could limit access.
- Pricing Competition: The introduction of alternative modalities, especially gene therapies, could impact pricing and market size.
- Patent Life: Patent protection extends until at least 2030, offering pricing power during that period.
Conclusion
NDC 69087-0237, under Relyvrio, occupies a niche in the ALS market, with pricing likely positioned between existing symptomatic treatments. Market growth will depend on clinical benefits, payor acceptance, and the competitive landscape evolving over the next five years.
Key Takeaways
- Initial pricing expected between $50,000 and $70,000 annually.
- The ALS market is projected to grow at roughly 7.3% CAGR, reaching approximately $300 million by 2030.
- Relyvrio's market entry faces competition from Riluzole and Edaravone but benefits from accelerated approval.
- Reimbursement strategies and clinical outcomes will influence long-term pricing and market share.
- Patent protection and pipeline developments are important factors in future revenue potential.
FAQs
-
What is the current status of Relyvrio’s approval?
Approved by the FDA in late 2022 via accelerated pathway for ALS, with confirmatory trials ongoing.
-
How does Relyvrio compare with existing ALS treatments?
It offers a novel mechanism targeting neurodegeneration, potentially improving disease management over older therapies like Riluzole and Edaravone.
-
What are the primary barriers to market penetration?
Clinician familiarity with existing drugs and reimbursement negotiations may delay widespread adoption.
-
Could biosimilars or gene therapies impact pricing?
Yes. New therapies could reduce pricing power after patent expiry or if they demonstrate superior efficacy.
-
What factors could alter the projected price range?
Clinical trial results, regulatory decisions, reimbursement policies, and competitive innovations.
Sources
[1] MarketsandMarkets, 2022. ALS Market Report.
[2] ALS Association, 2022. ALS Incidence and Prevalence Data.
